Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › INNOVACAP

INNOVACAP

Innova Captab Limited
Micro-capPharma ↗

What the six lenses say about INNOVACAP — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1164.4
2026-09-08
VWAP · 1Y anchor
₹821
+41.9% from VWAP
P/E · TTM
47.3×
TTM EPS ₹24.6
52-week range
98%
position low→high
RSI(14)
72
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How INNOVACAP’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD9100›

The actual numbers

Price vs VWAP (1y)+41.9%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+32.4%
Price vs 50-EMA+15.0%
RSI(14)72
RS vs Nifty 500 · 3M+29.4%
RS vs sector · 3M+23.4%
52-week range98%
Volume vs 30d avg0.35×
Volume vs 60d avg0.41×
ATR(14) · volatility55.1
Bollinger width · vol contraction0.168
FundamentalD857›

The actual numbers

Return on equity (ROE)12.9%
Operating margin12.7%
Net margin8.7%
Revenue growth · YoY+31.0%
EPS growth · YoY+9.9%
Debt / equity0.32×

Full 8-quarter history in the financials table below.

ValuationD29›

The actual numbers

P/E (TTM)47.3×
TTM EPS₹24.6
52-week range98%
CatalystD639›

The actual numbers

Earnings & momentum45
Capital actions11
Governance70

Every filing in the corporate-announcements panel below.

FlowD242›

The actual numbers

Promoter holding50.9%
Delivery · 30d avg47.5%
Up/down-day asymmetry-3.9pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D2 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
94
Conviction score 94/100 · avg-decile strength 5.5/10
Conviction score94/100›
TechnicalD9›
FundamentalD8›
ValuationD2›
CatalystD6›
FlowD2›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-0.4pp
+9.3pp
+25.5pp
+31.0pp
+74.0pp
+37.5pp
Nifty 500
Broad-market baseline
-0.5pp
+9.3pp
+24.5pp
+29.4pp
+68.3pp
+32.2pp
Sector
Own-sector index
—
—
+21.6pp
+23.4pp
+55.1pp
+11.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

INNOVACAP daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1164.40-11.00

Relative strength

RS vs baseline · rebased to 100

INNOVACAP ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
155.58-0.81

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)294318316315352380450448
↳ change QoQ—+8.1%-0.5%-0.5%+11.7%+8.0%+18.4%-0.4%
EBITDA (₹cr)4452514852526965
EBITDA margin15.0%16.3%16.1%15.2%14.8%13.7%15.3%14.5%
PAT (₹cr)2935343031304238
↳ change QoQ—+18.8%-2.3%-12.3%+3.3%-3.2%+40.0%-9.5%
Net margin10.0%11.0%10.8%9.5%8.8%7.9%9.3%8.5%
EPS (₹)5.156.125.975.175.425.187.376.65
D/E————————
YoY growth · Mar '26Revenue +42.2% YoYPAT +26.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 5 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Sep '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 22 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 Aug '26
    LOWgovernance
    Capacity addition
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 11 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 11 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds INNOVACAP

Mutual funds holding INNOVACAP (6)

FundWeightAUM ₹crGrade
Kotak Multicap Reg Gr0.58%29,274
Canara Robeco Small Cap Reg Gr1.12%14,231
Kotak Consumption Reg Gr1.20%1,759
WhiteOak Capital Phrm and Hlthcr Reg Gr1.10%825
Kotak Healthcare Reg Gr1.10%682
TRUSTMF Multi Cap Regular Growth1.04%681

ETFs holding INNOVACAP (0)

No tracked ETF holds INNOVACAP ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma